Home / Companies / Shenzhen Kangtai Biological Products Co., Ltd. / 31 May 2024
Shenzhen Kangtai Biological Products Co., Ltd.: meeting of 31 May 2024
Votes reported on Form N-PX, item by item
29 Form N-PX filers reported votes at the Shenzhen Kangtai Biological Products Co., Ltd. meeting of 31 May 2024. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
117 vote records from 29 filers. 0 of the 29 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
54 vote records from 27 filers. 0 of the 27 filers that marked the item either way voted against management.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
495 vote records from 29 filers. 25 of the 29 filers that marked the item either way voted against management.
OTHERIssuer
OTHER: management items
Management items in this category are shown together; filers word and number them differently.
15 vote records from 3 filers. 0 of the 3 filers that marked the item either way voted against management.
CAPITAL STRUCTURESecurity holder
Approve Downward Adjustment on Conversion Price of Convertible Bonds
51 vote records from 24 filers. 20 of the 24 filers that marked the item either way voted against management.
How the largest families voted
| Family | 5. Proposal |
|---|---|
| Vanguard | Against * |
| BlackRock and iShares | Against * |
| Fidelity | Against * |
| Dimensional | Against * |
| State Street and SPDR | For |
| Franklin Templeton | Against * |
| Nuveen and TIAA | Against * |
| Morgan Stanley, Eaton Vance and Calvert | Against * |
| Northern Trust and FlexShares | Against * |
| Lincoln Financial | For |
| Voya | Against * |
| BNY Mellon | Against * |
| Pacific Life funds | Against * |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Shenzhen Kangtai Biological Products Co., Ltd. meeting?
29 Form N-PX filers reported votes at the meeting of 31 May 2024. One proposal from security holders could be told apart in the filings. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Shenzhen Kangtai Biological Products Co., Ltd. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Shenzhen Kangtai Biological Products Co., Ltd.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Shenzhen Kangtai Biological Products Co., Ltd. with a meeting date within three days of 31 May 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.